The Technical Analyst
Verve Therapeutics, Inc. [VERV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Verve Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.96% $6.16
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 483.86 mill |
| EPS: | -3.12 |
| P/E: | -1.970 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 78.55 mill |
| Avg Daily Volume: | 1.297 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.970 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.34x |
| Company: PE -1.970 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.285 (-79.14%) $-4.88 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.11 - 7.21 ( +/- 17.06%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Nickerson Joan | Buy | 3 315 | Common Stock |
| 2024-04-01 | Nickerson Joan | Sell | 3 315 | Restricted Stock Units |
| 2024-04-02 | Nickerson Joan | Sell | 1 514 | Common Stock |
| 2024-02-14 | Ashe Andrew D. | Buy | 150 000 | Stock Option (right to buy) |
| 2024-02-14 | Ashe Andrew D. | Buy | 36 000 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 78.48 |
| Last 97 transactions |
| Buy: 4 843 517 | Sell: 1 394 833 |
Forecast:
16:00 - $6.16
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.16
Forecast 2: 16:00 - $6.16
Forecast 3: 16:00 - $6.16
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.16 (-0.96% ) |
| Volume | 0.791 mill |
| Avg. Vol. | 1.297 mill |
| % of Avg. Vol | 61.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VERV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $11.74 | N/A | Active |
|---|
VERV
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-25 17:15:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Verve Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 25, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of verve therapeutics, inc. ("verve" or "the company") (nasdaq:verv) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-19 10:30:00 - Press Release
Wolf Haldenstein Adler Freeman & Herz Llp Announces That It Is Investigating Verve Therapeutics, Inc. For Potential Violations Of Federal Securities Laws
New york , april 19, 2024 /prnewswire/ -- wolf haldenstein adler freeman & herz llp ("wolf haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claimson behalf of investors of verve therapeutics, inc. ("verve" or "the company") (nasdaq:verv) for violations of the securities laws. the focus of the investigation is to whether the company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
2024-04-19 04:00:00 - Press Release
Investor Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Verve Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 19, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of verve therapeutics, inc. ("verve" or "the company") (nasdaq:verv) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-18 08:00:00 - Press Release
Investor Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Verve Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 18, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of verve therapeutics, inc. ("verve" or "the company") (nasdaq:verv) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-16 23:30:00 - Press Release
Investor Action Alert: The Schall Law Firm Announces It Is Investigating Claims Against Verve Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 16, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of verve therapeutics, inc. ("verve" or "the company") (nasdaq:verv) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Latest News
2024-04-06 09:50:00 - The Motley Fool
After a Serious Setback, Is Verve Therapeutics a Buy?
Verve Therapeutics just had a major mishap in a clinical trial. However, it has a backup plan that's already in action.
2024-04-03 14:41:05 - Zacks Investment Research
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.
2024-04-02 09:08:00 - Market Watch
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback
Verve Therapeutics Inc. shares VERV, -3.69% dropped 35% premarket on Tuesday after the company paused enrollment in a clinical trial of its gene-editing treatment for heart disease.
2024-04-02 07:30:35 - Reuters
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event.
2024-03-21 16:19:51 - InvestorPlace
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
2024-02-19 16:08:49 - InvestorPlace
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive. Just look at CRISPR Therapeutics (NASADQ: CRSP ), for example.
2024-02-13 06:05:00 - InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.
2024-01-31 12:28:10 - InvestorPlace
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2024-01-17 12:04:45 - InvestorPlace
7 Mighty Healthcare Stocks Changing the Game of Medicine
With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.
2024-01-11 16:38:39 - InvestorPlace
3 Stocks to Buy in the Booming Field of Gene Editing
The promise of gene editing is moving closer to being a reality. If you're an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene editing stocks.